Search research articles
Contact Us
Filters
Showing results (341-350 of 551) with videos related to
Page
of 56
Sort By:
The Journal of Clinical Investigation
|
March 30, 2021
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin
Emily S Ford, Anton M Sholukh, RuthMabel Boytz, et al.
Plos One
|
September 18, 2009
Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
Laura Heath, Alan Fox, Jan McClure, et al.
The Journal of Infectious Diseases
|
April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
Paul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.
Annals of Internal Medicine
|
July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Dean Follmann, Holly E Janes, Olive D Buhule, et al.
Lancet (London, England)
|
June 24, 2008
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
Connie Celum, Anna Wald, James Hughes, et al.
Journal of the International AIDS Society
|
June 26, 2023
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
Deborah Donnell, Fei Gao, James P Hughes, et al.
Blood
|
April 4, 2002
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Paul A Carpenter, Frederick R Appelbaum, Lawrence Corey, et al.
The Journal of Infectious Diseases
|
April 3, 2007
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial
Karen E Mark, Lawrence Corey, Tze-Chiang Meng, et al.
Science Translational Medicine
|
April 8, 2011
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
Jared M Baeten, Erin Kahle, Jairam R Lingappa, et al.
Molecular Therapy. Methods & Clinical Development
|
September 6, 2021
Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques
Françoise Haeseleer, Yoshinori Fukazawa, Haesun Park, et al.
Page
of 56
Search research articles
Search
Showing results (341-350 of 551) with videos related to
Sort By:
Page
of 56
The Journal of Clinical Investigation
|
March 30, 2021
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin
Emily S Ford, Anton M Sholukh, RuthMabel Boytz, et al.
Plos One
|
September 18, 2009
Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
Laura Heath, Alan Fox, Jan McClure, et al.
The Journal of Infectious Diseases
|
April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
Paul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.
Annals of Internal Medicine
|
July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Dean Follmann, Holly E Janes, Olive D Buhule, et al.
Lancet (London, England)
|
June 24, 2008
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial
Connie Celum, Anna Wald, James Hughes, et al.
Journal of the International AIDS Society
|
June 26, 2023
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
Deborah Donnell, Fei Gao, James P Hughes, et al.
Blood
|
April 4, 2002
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Paul A Carpenter, Frederick R Appelbaum, Lawrence Corey, et al.
The Journal of Infectious Diseases
|
April 3, 2007
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial
Karen E Mark, Lawrence Corey, Tze-Chiang Meng, et al.
Science Translational Medicine
|
April 8, 2011
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
Jared M Baeten, Erin Kahle, Jairam R Lingappa, et al.
Molecular Therapy. Methods & Clinical Development
|
September 6, 2021
Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques
Françoise Haeseleer, Yoshinori Fukazawa, Haesun Park, et al.
Page
of 56